Trials / Completed
CompletedNCT01049347
Amitriptyline and Paroxetine Treatment of Major Depression
Hypothalamus-pituitary-adrenal System: Role of the Mineralocorticoid Receptor and Longitudinal Study in Depressed Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- Central Institute of Mental Health, Mannheim · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Activation of the hypothalamus-pituitary-adrenal system is monitored using saliva cortisol sampling during the antidepressant treatment with amitriptyline and paroxetine in moderately to severely depressed patients. Additionally, serum and plasma are sampled during the 5-week study period in order to study endocrine and metabolic parameters.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | amitriptyline | 150 mg oral, daily, single evening dose, 35 days |
| DRUG | paroxetine | 40 mg oral, single dose, morning, 35 days |
Timeline
- Start date
- 1997-10-01
- Primary completion
- 2000-05-01
- Completion
- 2000-05-01
- First posted
- 2010-01-14
- Last updated
- 2024-01-31
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01049347. Inclusion in this directory is not an endorsement.